MBII Pengajuan SEC - Marrone Bio Innovations Inc- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	54930082ZJZ17VOHI543
CIK	1441693

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Marrone Bio Innovations Inc

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 2, 2022	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36030 Pro Farm Group, Inc. (Formerly known as Marrone Bio Innovations, I
August 4, 2022	S-8 POS	As filed with the United States Securities and Exchange Commission on August 3, 2022 As filed with the United States Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	POS AM	As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	POS AM	As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	S-8 POS	As filed with the United States Securities and Exchange Commission on August 3, 2022 As filed with the United States Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	POS AM	As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	POS AM	As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	S-8 POS	As filed with the United States Securities and Exchange Commission on August 3, 2022 As filed with the United States Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	S-8 POS	As filed with the United States Securities and Exchange Commission on August 3, 2022 As filed with the United States Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	S-8 POS	As filed with the United States Securities and Exchange Commission on August 3, 2022 As filed with the United States Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	S-8 POS	As filed with the United States Securities and Exchange Commission on August 3, 2022 As filed with the United States Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	S-8 POS	As filed with the United States Securities and Exchange Commission on August 3, 2022 As filed with the United States Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	POS AM	As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No.
August 4, 2022	S-8 POS	As filed with the United States Securities and Exchange Commission on August 3, 2022 As filed with the United States Securities and Exchange Commission on August 3, 2022 Registration No.
July 15, 2022	SC 13D/A	MBII / Marrone Bio Innovations Inc / Ospraie Ag Science LLC - AMENDMENT NO. 12 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Ad
July 13, 2022	EX-3.1	Fifth Amended and Restated Certificate of Incorporation of Pro Farm Group, Inc. Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PRO FARM GROUP, INC. 1 FIRST: The name of the corporation (the ?Corporation?) is: Pro Farm Group, Inc. SECOND: The address of the Corporation?s registered office in the State of Delaware is The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801, New Castle County. The name of the Corporation?s registered
July 13, 2022	EX-3.2	Amended and Restated Bylaws of Pro Farm Group, Inc. Exhibit 3.2 PRO FARM GROUP, INC. BY-LAWS 1 MEETINGS OF STOCKHOLDERS 1.1 Place of Meeting and Notices Meetings of the stockholders of Pro Farm Group, Inc., a Delaware corporation (the ?Corporation?) shall be held at such place either within or without the State of Delaware as the Board of Directors may determine. 1.2 Annual and Special Meetings Annual meetings of stockholders shall be held, at a da
July 13, 2022	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 12, 2022 PRO FARM GROUP, INC.
July 11, 2022	8-K	Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2022 MARRONE BIO INNOVATIONS, INC.
July 11, 2022	EX-99.1	Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp. Exhibit 99.1 Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp. RALEIGH, N.C. ? July 11, 2022 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated a
June 30, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2022 MARRONE BIO INNOVATIONS, INC.
June 30, 2022	EX-10.1	Agreement Relating to Restricted Stock Units, dated June 30, 2022 Exhibit 10.1 AGREEMENT RELATING TO RESTRICTED STOCK UNITS This Agreement Relating to Restricted Stock Units (this ?Agreement?) is made and entered into effective June 30, 2022, by and between Marrone Bio Innovations, Inc. (the ?Company?) and Pamela Marrone (the ?Consultant?), and is acknowledged and agreed to by the parties to the Agreement and Plan of Merger, dated as of March 16, 2022, by and am
June 9, 2022	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101)? INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Con
May 19, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2022 MARRONE BIO INNOVATIONS, INC.
May 19, 2022	EX-10.1	Reserve Shortfall Letter to Invoice Purchase Agreement, dated May 17, 2022 Exhibit 10.1 May 17, 2022 Marrone Bio Innovations, Inc. 7780-420 Brier Creek Parkway Raleigh, NC 27617 Reference: Reserve Shortfall Letter to Invoice Purchase Agreement between LSQ Funding Group, L.C. (?LSQ?) and Marrone Bio Innovations, Inc. (?Seller?) Dated March 20, 2017 (the ?Agreement?) Dear Mr. Johnson: At your request in your capacity as an executive officer of Marrone Bio Innovations, Inc.
May 13, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 Or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 Marrone B
May 11, 2022	EX-99.1	Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results Exhibit 99.1 Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results RALEIGH, N.C., May 11, 2022 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: ? Higher sales of row crop products in the first quarte
May 11, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2022 MARRONE BIO INNOVATIONS, INC.
May 9, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
April 29, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
March 30, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36030 Marrone Bi
March 30, 2022	EX-4.4	Description of Registrant’s Securities Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of the common stock, $0.00001 par value per share (the ?Common Stock?), of Marrone Bio Innovations, Inc. (the ?Company?), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 193
March 29, 2022	EX-99.1	Joint Filing Agreement, dated March 29, 2022, by and among the Reporting Persons, as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene
March 29, 2022	SC 13G/A	MBII / Marrone Bio Innovations Inc / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 57165B106 (CUSIP Number) March 22, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
March 28, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 MARRONE BIO INNOVATIONS, INC.
March 28, 2022	EX-99.1	Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results Exhibit 99.1 Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results RALEIGH, N.C., March 28, 2022 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: ? Full year revenues
March 23, 2022	425	Filed by Marrone Bio Innovations, Inc. Filed by Marrone Bio Innovations, Inc. (Commission File No. 001-36030) Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Marrone Bio Innovations, Inc. (Commission File No.: 001-36030) Date: March 18, 2022 The following is a transcript of a conference presentation that was given
March 18, 2022	425	Filed by Marrone Bio Innovations, Inc. Filed by Marrone Bio Innovations, Inc. (Commission File No. 001-36030) Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Marrone Bio Innovations, Inc. (Commission File No.: 001-36030) Date: March 18, 2022 The following is a transcript of a conference presentation that was given
March 18, 2022	425	Filed by Marrone Bio Innovations, Inc. 425 1 form425.htm Filed by Marrone Bio Innovations, Inc. (Commission File No. 001-36030) Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Marrone Bio Innovations, Inc. (Commission File No.: 001-36030) Date: March 18, 2022 The following questions and answers were sent to employ
March 18, 2022	425	Filed by Marrone Bio Innovations, Inc. 425 1 form425.htm Filed by Marrone Bio Innovations, Inc. (Commission File No. 001-36030) Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Marrone Bio Innovations, Inc. (Commission File No.: 001-36030) The following is a form letter being sent to commercial partners of Marrone
March 17, 2022	425	Filed by Marrone Bio Innovations, Inc. Filed by Marrone Bio Innovations, Inc. (Commission File No. 001-36030) Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Marrone Bio Innovations, Inc. (Commission File No.: 001-36030) Date: March 17, 2022 The following is a transcript of a conference presentation that was given
March 17, 2022	425	Filed by Marrone Bio Innovations, Inc. Filed by Marrone Bio Innovations, Inc. (Commission File No. 001-36030) Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Marrone Bio Innovations, Inc. (Commission File No.: 001-36030) Date: March 17, 2022 [The following presentation was posted on Marrone Bio Innovations, Inc.?s
March 16, 2022	EX-99.2	Bioceres Crop Solutions and Marrone Bio Announce Merger Agreement Combined company creates global leader in sustainable agricultural solutions Bioceres obtains commitment for up to $45 million loan facility and conversion of existing convertible note Exhibit 99.2 Bioceres Crop Solutions and Marrone Bio Announce Merger Agreement Combined company creates global leader in sustainable agricultural solutions Bioceres obtains commitment for up to $45 million loan facility and conversion of existing convertible notes into shares and new term loan facility ROSARIO, Argentina, and RALEIGH, N.C. ? March 16, 2022 ? Bioceres Crop Solutions Corp. (NASDAQ:
March 16, 2022	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2022 MARRONE BIO INNOVATIONS, INC.
March 16, 2022	EX-99.1	Transaction Support Agreement for Company Securityholders Exhibit 99.1 Transaction Support Agreement for Company Securityholders This Transaction Support Agreement (this ?Agreement?) is made and entered into as of March 16, 2022, by and among Bioceres Crop Solutions Corp., a Cayman Islands exempted company (?Parent?), BCS Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (?Merger Sub?), and the stockholders of Marrone Bio I
March 16, 2022	EX-2.1	Agreement and Plan of Merger, dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Marrone Bio Innovations, Inc. Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among Bioceres Crop Solutions Corp., BCS MERGER SUB, INC. and Marrone Bio Innovations, Inc. Dated as of March 16, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 Section 1.01 Certain Definitions. 2 Section 1.02 Additional Definitions. 15 Section 1.03 Certain Interpretations. 19 ARTICLE II THE MERGER 20 Section
March 16, 2022	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2022 MARRONE BIO INNOVATI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2022 MARRONE BIO INNOVATIONS, INC.
February 22, 2022	EX-99.1	Marrone Bio Announces CFO Transition Exhibit 99.1 Marrone Bio Announces CFO Transition RALEIGH, N.C. ? February 22, 2022 - Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, announced today a transition of its Chief Financial Officer role. Current CFO Sue Cheung has chosen to resign for personal reasons, effective March 9, 2022. LaDon Johnson, a director with
February 22, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2022 MARRONE BIO INNOVATIONS, INC.
February 14, 2022	EX-99.1	Joint Filing Agreement, dated January 29, 2021, by and among the Reporting Persons, as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene
February 14, 2022	SC 13G/A	MBII / Marrone Bio Innovations Inc / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 57165B106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 10, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2022 MARRONE BIO INNOVATIONS, INC.
February 8, 2022	SC 13G	MBII / Marrone Bio Innovations Inc / ARDSLEY ADVISORY PARTNERS LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 57165B106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 8, 2022	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13G (including amendments thereto) with respect to the Common Stock of Marrone Bio Innovations Inc.
February 8, 2022	EX-2	IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP EXHIBIT 2 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP ARDSLEY ADVISORY PARTNERS LP ARDSLEY ADVISORY PARTNERS GP LLC ARDSLEY PARTNERS I GP LLC PHILLIP J. HEMPLEMAN ARDSLEY PARTNERS RENEWABLE ENERGY FUND, L.P.
January 18, 2022	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2022 MARRONE BIO INNOVATIONS, INC.
January 18, 2022	EX-99.1	Marrone Bio Innovations Issues Shareholder Letter Exhibit 99.1 Marrone Bio Innovations Issues Shareholder Letter Announces Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results RALEIGH, N.C., January 18, 2022 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released an update letter to share
January 6, 2022	EX-99.1	Marrone Bio’s Inventory Line of Credit Increased to Support Sales and Manufacturing Growth Exhibit 99.1 Marrone Bio?s Inventory Line of Credit Increased to Support Sales and Manufacturing Growth RALEIGH, N.C. ? January 6, 2022 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII) has expanded its existing inventory line of credit to support the company?s expectations for growth in sales and manufacturing capacity. Under an amended agreement with LSQ Funding Group, L.C., the company can access
January 6, 2022	EX-10.1	Amendment No. 1, dated as of December 30, 2021, to Amended Inventory Financing Addendum Exhibit 10.1 FIRST AMENDMENT TO THE AMENDED INVENTORY FINANCING ADDENDUM This First Amendment to the Amended Inventory Financing Addendum (this ?Amendment?), is dated as of December 30, 2021 (the ?Effective Date?) by and between LSQ Funding Group, L.C. (?Purchaser?) and Marrone Bio Innovations, Inc. (?Seller?). Capitalized terms used herein and not otherwise defined shall have the meaning ascribed
January 6, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2021 MARRONE BIO INNOVATIONS, INC.
December 17, 2021	SC 13D/A	MBII / Marrone Bio Innovations Inc / Ospraie Ag Science LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Ad
November 10, 2021	EX-99.1	Marrone Bio Innovations, Inc. Reports Third-Quarter 2021 Financial Results Exhibit 99.1 Marrone Bio Innovations, Inc. Reports Third-Quarter 2021 Financial Results DAVIS, Calif. ? November 10, 2021 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the third quarter ended September 30, 2021. Key results include: ? Strategic focus on global expansion in the
November 10, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 MARRONE BIO INNOVATIONS, INC.
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 Or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 Marro
November 10, 2021	SC 13G/A	MBII / Marrone Bio Innovations Inc / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 57165B106 (CUSIP Number) October 29, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
November 8, 2021	EX-99.1	Marrone Bio Innovations Receives Nasdaq Notice Regarding Failure to Satisfy a Continued Listing Rule Exhibit 99.1 Marrone Bio Innovations Receives Nasdaq Notice Regarding Failure to Satisfy a Continued Listing Rule DAVIS, Calif. ? November 8, 2021 ? Marrone Bio Innovations, Inc. (Nasdaq: MBII) today announced that it has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) as a result
November 8, 2021	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2021 MARRONE BIO INNOVATIONS, INC.
August 30, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 24, 2021 MARRONE BIO INNOVATIONS, INC.
August 16, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2021 MARRONE BIO INNOVATIONS, INC.
August 16, 2021	EX-99.1	Marrone Bio Innovations, Inc. Reports Second-Quarter 2021 Financial Results Exhibit 99.1 Marrone Bio Innovations, Inc. Reports Second-Quarter 2021 Financial Results DAVIS, Calif. ? August 16, 2021 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the second quarter ended June 30, 2021. Key results include: ? The net loss in the second quarter was $3 millio
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 Or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 Marrone Bi
July 9, 2021	SC 13G/A	MBII / Marrone Bio Innovations Inc / MACQUARIE GROUP LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 57165B106 (CUSIP Number) June 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
May 28, 2021	8-K	Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2021 MARRONE BIO INNOVATIONS, INC.
May 13, 2021	EX-99.2	Marrone Bio Innovations Issues Shareholder Letter Exhibit 99.2 Marrone Bio Innovations Issues Shareholder Letter DAVIS, Calif., May 13, 2021 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released an update letter to shareholders from Chief Executive Officer Kevin Helash. Dear Shareholders, Today we a
May 13, 2021	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 MARRONE BIO INNOVATIONS, INC.
May 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 Or [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 Marro
May 13, 2021	EX-99.1	Marrone Bio Innovations, Inc. Reports First-Quarter 2021 Financial Results Exhibit 99.1 Marrone Bio Innovations, Inc. Reports First-Quarter 2021 Financial Results DAVIS, Calif. ? May 13, 2021 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII) has provided its financial results for the first quarter ended March 31, 2021. Key results include: ? First-quarter revenues increased 14% for 11th consecutive quarter of growth. ? Gross profit increased 25%, with gross margins of 63.1%
April 28, 2021	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2021 MARRONE BIO INNOVATIONS, INC.
April 28, 2021	EX-99.1	Marrone Bio Innovations Issues Shareholder Letter Exhibit 99.1 Marrone Bio Innovations Issues Shareholder Letter DAVIS, Calif., April 28, 2021 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released an update letter to shareholders from Chief Executive Officer Kevin Helash. Dear Shareholders, Spring h
April 26, 2021	DEF 14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo
April 9, 2021	PRE 14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, fo
April 5, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2021 MARRONE BIO INNOVATIONS, INC.
March 26, 2021	S-3/A	- As filed with the Securities and Exchange Commission on March 26, 2021 Registration No.
March 26, 2021	10-K/A	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number
March 24, 2021	CORRESP	March 24, 2021 March 24, 2021 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.
March 23, 2021	EX-99.2	Marrone Bio Innovations Issues Shareholder Letter Exhibit 99.2 Marrone Bio Innovations Issues Shareholder Letter DAVIS, Calif., March 23, 2021 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII) (?Marrone Bio?), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released a letter to shareholders from Chief Executive Officer, Kevin Helash. Dear Shareholders,
March 23, 2021	8-K	Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2021 MARRONE BIO INNOVATIONS, INC.
March 23, 2021	EX-99.1	Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2020 Financial Results Exhibit 99.1 Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2020 Financial Results DAVIS, Calif. – March 23, 2021 – Marrone Bio Innovations, Inc. (NASDAQ: MBII) has provided its financial results for the fourth quarter and full year ended December 31, 2020. Key results include: ● Revenues increased 31% in fiscal year 2020, driven by expanded use of the company’s biological solu
March 23, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36030 Marron
March 16, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Ad
February 25, 2021	8-K	Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2021 MARRONE BIO INNOVATIONS, INC.
February 12, 2021	EX-99.1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
February 12, 2021	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13D (including amendments thereto) with respect to the Common Stock of Marrone Bio Innovations, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to su
February 12, 2021	EX-99.3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
February 12, 2021	SC 13D/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No. 6) (Rule 13d-101) information to be included in statements filed pursuant to rules 13d-1(a) and amendments thereto filed pursuant to rule 13d-2(a)1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No.
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 3* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Marrone Bio Innovations. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 3* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 57165B106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 12, 2021	EX-99.2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
February 8, 2021	EX-4.23	Form of Indenture Exhibit 4.23 MARRONE BIO INNOVATIONS, INC. AND Trustee INDENTURE Dated as of Debt Securities Reconciliation and tie between Trust Indenture Act of 1939, as amended, and the Indenture Trust Indenture Act Section Indenture Section (S)310(a)(1) 6.8 (a)(2) 6.8 (b) 6.9 (S)312(a) 7.1 (b) 7.2 (c) 7.2 (S)313(a) 7.3 (b)(2) 7.3 (c) 7.3 (d) 7.3 (S)314(a) 7.4 (c)(1) 1.2 (c)(2) 1.2 (e) 1.2 (f) 1.2 (S)316(a) (l
February 8, 2021	S-3	Power of Attorney (included on signature page) † As filed with the Securities and Exchange Commission on February 8, 2021 Registration No.
February 3, 2021	EX-99.1	February 3, 2021 Exhibit 99.1 February 3, 2021 Dear Shareholders: There is a rhythm to agriculture that is predictable even in unpredictable times. The first half of the year starts strong, as Southern Hemisphere row crops mature and move toward harvest. In the Northern Hemisphere, orchards are being pruned and prepped for bud set and pollination. Row crop farmers are finalizing seed and input selections, cautious
February 3, 2021	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 3, 2021 MARRONE BIO INNOVATIONS, INC.
January 29, 2021	EX-99.1	Marrone Bio Appoints Sue Cheung New Chief Financial Officer Exhibit 99.1 Marrone Bio Appoints Sue Cheung New Chief Financial Officer DAVIS, Calif. – Jan. 28, 2021 – Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today that Suping (Sue) Cheung has been appointed chief financial officer, effective Feb. 18, 2021
January 29, 2021	EX-10.2	Change in Control Agreement, dated as of January 26, 2021, by and between Marrone Bio Innovations, Inc. and Suping Liu Cheung. Exhibit 10.2 CHANGE IN CONTROL AGREEMENT This Change in Control Agreement (the “Agreement”) is made and entered into by and between Suping Liu Cheung (“Executive”) and Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”), effective as of Executive’s first date of employment by the Company (the “Effective Date”). RECITALS 1. It is expected that the Company from time to time will co
January 29, 2021	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene
January 29, 2021	EX-10.1	Offer letter, effective January 25, 2021, by and between Marrone Bio Innovations, Inc. and Suping Liu Cheung. Exhibit 10.1 January 7, 2021 Ms. Suping Liu Cheung 20987 Greenleaf Drive Cupertino, CA 95014 Dear Suping, I am pleased to offer you the full-time position of Chief Financial Officer, with Marrone Bio Innovations, Inc. (the “Company”), reporting to Kevin Helash, Chief Executive Officer. Your actual start date will be determined upon successfully passing your drug test and background check. We antic
January 29, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 25, 2021 MARRONE BIO INNOVATIONS, INC.
January 29, 2021	SC 13G/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 57165B106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
January 8, 2021	S-8	- As filed with the Securities and Exchange Commission on January 8, 2021 Registration No.
January 5, 2021	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2020 MARRONE BIO INNOVATIONS, INC.
January 5, 2021	EX-4.1	Amendment to the Van Herk Warrant, by and among, Marrone Bio Innovations, Inc., Ospraie Ag Science LLC, and Van Herk Investments B.V., dated December 29, 2020. Exhibit 4.1 AMENDMENT TO THE VAN HERK WARRANT This Amendment to the Van Herk Warrant (this “Amendment”) is entered into as of December 29, 2020 (the “Amendment Date”), by Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”), Ospraie Ag Science LLC (“Ospraie” or the “Lead Investor”) and Van Herk Investments B.V. (“Van Herk”). Reference is made to (a) the Securities Purchase Agreeme
January 5, 2021	424B3	29,881,162 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-251284 29,881,162 Shares Common Stock This prospectus relates to the possible resale or other disposition, from time to time, of up to 29,881,162 shares of our common stock previously issued and issuable upon exercise of warrants to purchase shares of our common stock by the selling stockholders named in this prospectus or in supplements to thi
January 5, 2021	EX-99.1	Marrone Bio Provides Update on Warrant Transactions; No New Securities Offered Exhibit 99.1 Marrone Bio Provides Update on Warrant Transactions; No New Securities Offered DAVIS, Calif., (Jan. 5, 2021) (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII), a leading provider of effective and environmentally responsible pest management and plant health products, today provided an update on its warrant transactions. Effective Dec. 29, 2020, an amendment was made to a
December 30, 2020	CORRESP	- December 30, 2020 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.
December 30, 2020	CORRESP	- December 30, 2020 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.
December 17, 2020	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Add
December 11, 2020	S-3	- S-3 1 forms-3.htm As filed with the Securities and Exchange Commission on December 11, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Marrone Bio Innovations, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5137161 (State or other jurisdiction of incorporatio
November 9, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 Or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 Marro
November 9, 2020	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2020 MARRONE BIO INNOVATIONS, INC.
November 9, 2020	EX-99.1	Marrone Bio Innovations, Inc. Reports Third-Quarter 2020 Financial Results Expansion in international and seed treatment markets led revenue growth and gross margin improvement Exhibit 99.1 Marrone Bio Innovations, Inc. Reports Third-Quarter 2020 Financial Results Expansion in international and seed treatment markets led revenue growth and gross margin improvement DAVIS, Calif. ? Nov. 9, 2020 ? Marrone Bio Innovations, Inc. (NASDAQ: MBII) (?Marrone Bio? or the ?company?), an international leader in providing growers with sustainable bioprotection and plant health solutio
November 9, 2020	EX-99.2	November 9, 2020 Exhibit 99.2 November 9, 2020 Dear Shareholders: It?s been an exciting first three months with Marrone Bio for me, and I?d like to start by recognizing the unwavering commitment of everyone in the company to meeting our customers? needs and contributing to their success. I have seen it demonstrated in every aspect of the business, and our results so far this year reflect this passion. I want to re
November 2, 2020	EX-99.1	Marrone Bio Innovations Appoints Lara L. Lee to Board of Directors Prominent Business Leader Brings 30+ Years of Executive Leadership Experience to the Company’s Board of Directors Exhibit 99.1 Marrone Bio Innovations Appoints Lara L. Lee to Board of Directors Prominent Business Leader Brings 30+ Years of Executive Leadership Experience to the Company’s Board of Directors DAVIS, Calif., Nov. 2, 2020 — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support
November 2, 2020	8-K	Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2020 MARRONE BIO INNOVATIONS, INC.
October 19, 2020	EX-99.1	Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update Exhibit 99.1 Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update DAVIS, Calif., Oct. 19, 2020 — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released a letter to shareholders from Chief Executive Officer, K
October 19, 2020	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2020 MARRONE BIO INNOVATIONS, INC.
October 13, 2020	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / Ospraie Ag Science LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Add
October 6, 2020	PX14A6G	- Notice of Exempt Solicitation (MBII) Marrone Bio Innovations Inc. (MBII) Shareholder Alert Voluntary submission by James McRitchie, 9295 Yorkship Ct., Elk Grove, CA 95758 Shareholder since 2016 Please vote for Proposal No. 5 before October 28th Stockholder Proposal: Phase in Simple Majority Vote The proposal’s description in the Proxy Voting Instructions Form (VIF) violates SEC Rule 14a-4(a)(3) Ru
September 25, 2020	DEF 14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo
September 23, 2020	EX-99.1	Marrone Bio Innovations Announces Plans for CFO Succession Exhibit 99.1 Marrone Bio Innovations Announces Plans for CFO Succession President and CFO James Boyd to Retire from the Company; Search Process for New CFO Underway DAVIS, Calif., Sep. 22, 2020 — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, a
September 23, 2020	EX-10.2	Consulting Agreement, dated September 21, 2020, between Marrone Bio Innovations, Inc., and James B. Boyd Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH PORTIONS ARE MARKED AS INDICATED WITH BRACKETS (“[***]”) BELOW MARRONE BIO INNOVATIONS, INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is made and entered into as of the 21 day of September 2020 (“
September 23, 2020	EX-10.1	Employment Separation Agreement, dated September 21, 2020, between James B. Boyd and Marrone Bio Innovations, Inc. Exhibit 10.1 EMPLOYMENT SEPARATION AGREEMENT This Employment Separation Agreement (the “Agreement”) is made and entered into by and between James B. Boyd (“Executive”) and Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”), effective as of September, 21 2020 (the “Effective Date”). W I T N E S S E T H: WHEREAS, Executive is the President and Chief Financial Officer of the Compan
September 23, 2020	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2020 MARRONE BIO INNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2020 MARRONE BIO INNOVATIONS, INC.
September 11, 2020	PRE 14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, fo
August 11, 2020	8-K	Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2020 MARRONE BIO INNOVATIONS, INC.
August 10, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 Or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 Marrone Bi
August 10, 2020	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2020 MARRONE BIO INNOVATIONS, INC.
August 10, 2020	EX-99.2	MARRONE BIO INNOVATIONS Exhibit 99.2 MARRONE BIO INNOVATIONS August 10, 2020 To our shareholders: It is a pleasure to reach out to you today as the company’s new CEO. I am excited by the opportunity, and honored to be chosen to lead the organization to its next level of success. As you will see in our Q2 earnings release today, our financial results point both to the momentum we have created, and to the opportunity to co
August 10, 2020	EX-99.1	Marrone Bio Innovations, Inc. Reports Second Quarter and First Half 2020 Financial Results Second-Quarter Revenue Increased 74% to Record $12.2 Million Record Gross Margins of 60.6% Mark Seventh Consecutive Quarter of 50%+ Margins Exhibit 99.1 Marrone Bio Innovations, Inc. Reports Second Quarter and First Half 2020 Financial Results Second-Quarter Revenue Increased 74% to Record $12.2 Million Record Gross Margins of 60.6% Mark Seventh Consecutive Quarter of 50%+ Margins DAVIS, Calif. – August 10, 2020 – Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio” or the “Company”), an international leader in providing grower
July 24, 2020	EX-99.1	Marrone Bio Innovations to Report Second Quarter 2020 Results on Monday, August 10th at 4:30 p.m. Eastern Time Company Concurrently Confirms August 3rd Start Date for Incoming Chief Executive Officer and Director Kevin Helash Exhibit 99.1 Marrone Bio Innovations to Report Second Quarter 2020 Results on Monday, August 10th at 4:30 p.m. Eastern Time Company Concurrently Confirms August 3rd Start Date for Incoming Chief Executive Officer and Director Kevin Helash DAVIS, Calif., July 24, 2020 — Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant
July 24, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2020 MARRONE BIO INNOVATIONS, INC.
July 6, 2020	EX-99.2	To Our Shareholders: Exhibit 99.2 To Our Shareholders: As was announced today, it is my distinct privilege to take on the leadership of Marrone Bio as its next chief executive officer. I am grateful to the board of directors for its support, and I share in its vision to build on the company’s recent successes and drive a clear path to profitability for our shareholders. When I join Marrone Bio later this quarter, I wi
July 6, 2020	EX-10.2	Change in Control Agreement, dated as of July 3, 2020, by and between Marrone Bio Innovations, Inc. and Kevin Helash Exhibit 10.2 CHANGE IN CONTROL AGREEMENT This Change in Control Agreement (the “Agreement”) is made and entered into by and between Kevin Helash (“Executive”) and Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”), effective as of Executive’s first date of employment by the Company (the “Effective Date”). RECITALS 1. It is expected that the Company from time to time will conside
July 6, 2020	EX-99.1	Marrone Bio Appoints Kevin Helash as Chief Executive Officer Agricultural Industry Veteran Brings Extensive Experience in Global Markets and Biological Solutions Exhibit 99.1 Marrone Bio Appoints Kevin Helash as Chief Executive Officer Agricultural Industry Veteran Brings Extensive Experience in Global Markets and Biological Solutions DAVIS, Calif., July 6, 2020 —Marrone Bio Innovations, Inc., (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to global agricultural needs, today announced
July 6, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2020 MARRONE BIO INNOVATIONS, INC.
July 6, 2020	EX-10.1	Offer letter, dated July 3, 2020, by and between Marrone Bio Innovations, Inc. and Kevin Helash Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH PORTIONS ARE MARKED AS INDICATED WITH BRACKETS (“[***]”) BELOW July 3, 2020 Kevin Helash 5840 Valle Vista Court Granite Bay California 95746 Dear Kevin, I am pleased to offer you the full-time position of Chief Execu
May 11, 2020	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 MARRONE BIO INNOVATIONS, INC.
May 11, 2020	EX-99.1	Marrone Bio Innovations, Inc. Reports First Quarter 2020 Financial Results Seventh Consecutive Quarter of Year Over Year Revenue Growth Realized in Challenging Environment for Agricultural Production Record Gross Margins Mark Sixth Consecutive Quarte Exhibit 99.1 Marrone Bio Innovations, Inc. Reports First Quarter 2020 Financial Results Seventh Consecutive Quarter of Year Over Year Revenue Growth Realized in Challenging Environment for Agricultural Production Record Gross Margins Mark Sixth Consecutive Quarter of 50+ Percent Performance DAVIS, Calif. – May 11, 2020 – Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio” or the “Company”)
May 11, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 Or [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 Marro
May 5, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2020 MARRONE BIO INNOVATIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36030 20-5137161 (State or other jurisdiction (Commission (I.R.S. Employe
May 1, 2020	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / Ospraie Ag Science Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Add
April 30, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2020 MARRONE BIO INNOVATIONS, INC.
April 30, 2020	EX-4.1	Form of Warrant issuable pursuant to the Warrant Exchange Agreement (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on April 30, 2020) Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR ASSIGNED ONLY (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES AC
April 30, 2020	EX-10.2	Registration Rights Agreement, dated April 29, 2020, by and among Marrone Bio Innovations, Inc., Ospraie Ag Science LLC, Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund, and Ivy VIP Science & Technology, and the Waddell Investors Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 29, 2020, by and among Marrone Bio Innovations, Inc., a Delaware corporation, with headquarters located at 1540 Drew Avenue, Davis, CA 95618 (the “Company”), and the Investors (as hereinafter defined). WHEREAS: A. Pursuant to the Warrant Exchange Agreement (the “Warrant Exchange Agreement
April 30, 2020	EX-10.1	Warrant Exchange Agreement, dated April 29, 2020, between Marrone Bio Innovations, Inc., Ospraie Ag Science LLC, Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund, and Ivy VIP Science & Technology, and the Waddell Investors Exhibit 10.1 WARRANT EXCHANGE AGREEMENT This Warrant Exchange Agreement (this “Agreement”) is entered into as of April 29, 2020, by and among Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”), Ospraie Ag Science LLC (“Ospraie”), Ardsley Partners Renewable Energy Fund, L.P. (“Ardsley”), National Securities Corporation (“NSC”), Ivan Saval (Mr. Saval, together with NSC, Ospraie an
April 30, 2020	EX-99.1	Marrone Bio Announces Warrant Exchange Agreement Exhibit 99.1 Marrone Bio Announces Warrant Exchange Agreement DAVIS, Calif., April 30, 2020 — Marrone Bio Innovations, Inc. (Nasdaq: MBII) (the “Company” or “Marrone Bio”) an international leader in sustainable bioprotection and plant health solutions, has signed a warrant exchange agreement with existing institutional investors that immediately reduces the total number of outstanding warrants by
April 24, 2020	EX-99.1	Marrone Bio Innovations Receives Nasdaq Notice Regarding Failure to Satisfy a Continued Listing Rule Exhibit 99.1 Marrone Bio Innovations Receives Nasdaq Notice Regarding Failure to Satisfy a Continued Listing Rule DAVIS, Calif., April 24, 2020 — Marrone Bio Innovations, Inc. (Nasdaq: MBII) (the “Company”) today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company of its noncompliance with Nasdaq Listing Rul
April 24, 2020	8-K	Financial Statements and Exhibits, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2020 MARRONE BIO INNOVATIONS, INC.
April 17, 2020	EX-10.1	Promissory Note dated April 13, 2020, between Five Star Bank and Marrone Bio Innovations, Inc. Exhibit 10.1 U.S. Small Business Administration NOTE SBA Loan # 3889207101 SBA Loan Name Marrone Bio Innovations, Inc. Date 04/13/2020 Loan Amount $1,723,000.00 Interest Rate 1.00% Borrower Marrone Bio Innovations, Inc. Operating Company N/A Lender Five Star Bank 1) PROMISE TO PAY: Subject to the terms of forgiveness identified in section 5) below, in return for the Loan, Borrower promises to pay
April 17, 2020	EX-99.1	Marrone Bio Innovations Secures $1.7 Million Loan Under Paycheck Protection Program Provision of CARES Act Company Expects Full Loan Forgiveness Under Terms; Funds to be Used to Retain Workforce During Critical Spring Growing Season for U.S. Farmers Exhibits 99.1 Marrone Bio Innovations Secures $1.7 Million Loan Under Paycheck Protection Program Provision of CARES Act Company Expects Full Loan Forgiveness Under Terms; Funds to be Used to Retain Workforce During Critical Spring Growing Season for U.S. Farmers DAVIS, Calif., April 17, 2020 — Marrone Bio Innovations Inc. (NASDAQ: MBII) (the “Company” or “Marrone Bio”), an international leader in
April 17, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2020 MARRONE BIO INNOVATIONS, INC.
April 16, 2020	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / Ospraie Ag Science Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Add
March 30, 2020	424B3	152,641,473 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237331 152,641,473 Shares Common Stock This prospectus relates to the possible resale or other disposition, from time to time, of up to 152,641,473 shares of our common stock previously issued and issuable upon exercise of warrants to purchase shares of our common stock by the selling stockholders named in this prospectus or in supplements to t
March 27, 2020	CORRESP	- March 27, 2020 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.
March 20, 2020	S-1	MBII / Marrone Bio Innovations, Inc. S-1 - Registration Statement - As filed with the Securities and Exchange Commission on March 20, 2020 Registration No.
March 20, 2020	S-8	MBII / Marrone Bio Innovations, Inc. S-8 - - As filed with the Securities and Exchange Commission on March 20, 2020 Registration No.
March 16, 2020	10-K	MBII / Marrone Bio Innovations, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36030 Marron
March 16, 2020	EX-10.33	Employment Separation Agreement, dated December 1, 2019, between Marrone Bio Innovations, Inc. and Dr. Pamela G. Marrone. Exhibit 10.33 EMPLOYMENT SEPARATION AGREEMENT This Employment Separation Agreement (the “Agreement”) is made and entered into by and between Pamela Marrone (“Executive”) and Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”), effective as of December 1, 2019 (the “Effective Date”). W I T N E S S E T H: WHEREAS, Executive is the Chief Executive Officer of the Company and a member
March 16, 2020	EX-21.1	List of Subsidiaries of Marrone Bio Innovations, Inc. Exhibit 21.1 LIST OF SUBSIDARIES OF MARRONE BIO INNOVATIONS, INC. Marrone Bio Innovations, Inc. (Delaware) Marrone Michigan Manufacturing, LLC (Michigan) Pro Farm Inc. (Delaware) Pro Farm Technologies Oy (Finland) Pro Farm International Oy (Finland) Pro Farm OU (Estonia) Pro Farm Technogies Comercio de Insumos Agricolas do Braisil Ltda.(Brazil) Glinatur SA (Uruguay) Pro Farm Russia, LLC. (Russia)
March 16, 2020	EX-10.34	Consulting Agreement, dated December 1, 2019, between Marrone Bio Innovations, Inc. and Dr. Pamela G. Marrone. Exhibit 10.34 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (the “Agreement”), dated December 1, 2019, is entered into between Pamela Marrone (“Consultant”) and Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”). WHEREAS, for the parties’ mutual benefit, following Consultant’s retirement from service as an employee and Chief Executive Officer of the Company pu
March 16, 2020	EX-4.14	Description of Registrant’s Securities Exhibit 4.14 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of the common stock, $0.00001 par value per share (the “Common Stock”), of Marrone Bio Innovations, Inc. (the “Company”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 19
March 16, 2020	EX-4.11	Form of Warrants issued by Marrone Bio Innovations, Inc. in connection with June 2017 Consulting Agreement (incorporated by reference to Exhibit 4.11 to the Company’s Annual Report on Form 10-K, as filed with the SEC on March 16, 2020) Exhibit 4.11 THE SECURITIES REPRESENTED HEREBY (AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF) HAVE BEEN ISSUED PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEQT OF THE COMPANY THAT SUCH SECURITIES MAY NOT BE OFFERED, SOLD PLEDGED
March 12, 2020	EX-99.1	Marrone Bio Innovations, Inc. Reports Record Fourth Quarter and Full Year 2019 Financial Results Full Year Revenues Rose 38 Percent to a Record $29.4 Million, Driving Record Annual Gross Margins of 54.9 Percent Record Fourth Quarter Revenues Increase Exhibit 99.1 CONFIDENTIAL MARRONE BIO INNOVATIONS DRAFT Marrone Bio Innovations, Inc. Reports Record Fourth Quarter and Full Year 2019 Financial Results Full Year Revenues Rose 38 Percent to a Record $29.4 Million, Driving Record Annual Gross Margins of 54.9 Percent Record Fourth Quarter Revenues Increased 17 Percent, with Record Gross Margins of 55.8 Percent DAVIS, Calif. – March 12, 2020 – Marro
March 12, 2020	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2020 MARRONE BIO INNOVATIONS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36030 20-5137161 (State or Other Jurisdiction of Incorpora
March 11, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2020 MARRONE BIO INNOVATIONS, INC.
March 6, 2020	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / Ospraie Ag Science Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Add
February 14, 2020	SC 13G/A	MBII / Marrone Bio Innovations, Inc. / WADDELL & REED FINANCIAL INC - MARRONE BIO INNOVATIONS, INC. Passive Investment Marrone Bio Innovations, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 2* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 57165B106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
February 14, 2020	EX-99.2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
February 14, 2020	SC 13G/A	MBII / Marrone Bio Innovations, Inc. / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 57165B106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 14, 2020	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene
February 14, 2020	EX-99.3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
February 14, 2020	EX-99.1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
February 7, 2020	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / ARDSLEY ADVISORY PARTNERS - SC 13D/A Activist Investment SC 13D/A 1 marrone13da5.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No. 5) (Rule 13d-101) information to be included in statements filed pursuant to rules 13d-1(a) and amendments thereto filed pursuant to rule 13d-2(a)1 Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 57165B106 (CUSIP Number) Steve Napoli
February 7, 2020	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13D (including amendments thereto) with respect to the Common Stock of Marrone Bio Innovations, Inc.
January 9, 2020	EX-99.1	Marrone Bio Innovations Announces New $23 Million Accounts-Receivable and Inventory-Backed Credit Facilities New Credit Facilities to Address Working Capital Required to Support Growing Sales Exhibit 99.1 Marrone Bio Innovations Announces New $23 Million Accounts-Receivable and Inventory-Backed Credit Facilities New Credit Facilities to Address Working Capital Required to Support Growing Sales DAVIS, Calif., Jan. 9, 2020 — Marrone Bio (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today announced a $13.0 million expansion of its e
January 9, 2020	EX-10.1	Amendment No. 2 dated as of January 7, 2020, to Invoice Purchase Agreement dated March 24, 2017 Exhibit 10.1 SECOND AMENDMENT TO INVOICE PURCHASE AGREEMENT This Second Amendment (“Second Amendment”) to the Invoice Purchase Agreement entered into on March 24, 2017 (“Invoice Purchase Agreement”) is made and entered into on January 6, 2020, by and between Marrone Bio Innovations, Inc., a Delaware corporation (the “Seller”) with offices located at 1540 Drew Ave, Davis, CA 95618 and LSQ Funding G
January 9, 2020	EX-10.2	Amended Inventory Financing Addendum, dated as of January 6, 2020 Exhibit 10.2 AMENDED INVENTORY FINANCING ADDENDUM This Amended Inventory Financing Addendum to the Invoice Purchase Agreement (“Addendum”) is dated as of January 6, 2020 by and between Marrone Bio Innovations, Inc., a Delaware Corporation (“Seller”) and LSQ Funding Group, L.C. (“Purchaser”). RECITALS A. Seller and Purchaser are parties to the Invoice Purchase Agreement pursuant to which Purchaser
January 9, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2020 MARRONE BIO INNOVATIONS, INC.
January 3, 2020	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / Ospraie Ag Science Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Add
December 31, 2019	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13D (including amendments thereto) with respect to the Common Stock of Marrone Bio Innovations, Inc.
December 31, 2019	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / ARDSLEY ADVISORY PARTNERS - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No.
December 20, 2019	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / Ospraie Ag Science Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Add
December 2, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2019 MARRONE BIO INNOVATIONS, INC.
December 2, 2019	EX-99.1	Marrone Bio Innovations Announces Plans for CEO Succession Founder and CEO Pamela Marrone to Retire from the Company; Search Process for New CEO Under Way Exhibit 99.1 Marrone Bio Innovations Announces Plans for CEO Succession Founder and CEO Pamela Marrone to Retire from the Company; Search Process for New CEO Under Way DAVIS, Calif. – December 2, 2019 — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, announced today that company founder Dr. Pamela Marrone will ret
November 25, 2019	EX-99.1	Audited financial statements of Pro Farm Technologies OY as of and for the years ended December 31, 2018 and 2017. Exhibit 99.1
November 25, 2019	EX-99.2	MARRONE BIO INNOVATIONS UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.2 MARRONE BIO INNOVATIONS UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Introduction On August 7, 2019, Marrone Bio Innovations, Inc. (“MBI” or the “Company”) entered into a share purchase agreement with Pro Farm Technologies OY, a Finnish limited company (“Pro Farm”) for the purchase of all the issued and outstanding equity interests in Pro Farm. On September 13, 2019, th
November 25, 2019	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No.
November 19, 2019	10-Q	MBII / Marrone Bio Innovations, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 Or [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 M
November 19, 2019	EX-10.3	Asset Purchase Agreement dated September 10, 2019, by and among Austin Grant, Inc., Marrone Bio Innovations, Inc., and Bill Grant and Lucie Grant CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
November 12, 2019	NT 10-Q	MBII / Marrone Bio Innovations, Inc. NT 10-Q - - SEC FILE NUMBER 001-36030 CUSIP NUMBER 57165B106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 12, 2019	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2019 MARRONE BIO INNOVATIONS, INC.
November 12, 2019	EX-99.1	Marrone Bio Innovations, Inc. Reports Third Quarter and First Nine Months 2019 Financial Results Revenues Increased 46 Percent Year to Date to $22.7 Million; Increased 28 Percent in Third Quarter 2019 to $7.0 Million Gross Margins of 50+ Percent Achi Marrone Bio Innovations, Inc. Reports Third Quarter and First Nine Months 2019 Financial Results Revenues Increased 46 Percent Year to Date to $22.7 Million; Increased 28 Percent in Third Quarter 2019 to $7.0 Million Gross Margins of 50+ Percent Achieved in Four Consecutive Quarters DAVIS, Calif. – November 12, 2019 – Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustain
October 11, 2019	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 8, 2019 MARRONE BIO INNOVATIONS, INC.
September 16, 2019	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2019 MARRONE BIO INNOVATIONS, INC.
September 16, 2019	EX-99.1	Marrone Bio Announces Closing of Pro Farm Technologies Acquisition New Subsidiary Enters into Strategic, Long-Term Exclusive Commercial Agreement in Europe with Corteva Agriscience Marrone Bio Announces Closing of Pro Farm Technologies Acquisition New Subsidiary Enters into Strategic, Long-Term Exclusive Commercial Agreement in Europe with Corteva Agriscience DAVIS, Calif.
September 12, 2019	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / ARDSLEY ADVISORY PARTNERS - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No.
September 12, 2019	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13D (including amendments thereto) with respect to the Common Stock of Marrone Bio Innovations, Inc.
September 11, 2019	EX-99.1	Marrone Bio Acquires Jet Ag and Jet Oxide Product Lines; Significantly Expands Opportunity in Agricultural Bioprotection Market New product lines provide immediate revenue growth and near-term earnings accretion Marrone Bio Acquires Jet Ag and Jet Oxide Product Lines; Significantly Expands Opportunity in Agricultural Bioprotection Market New product lines provide immediate revenue growth and near-term earnings accretion DAVIS, Calif.
September 11, 2019	8-K	Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 10, 2019 MARRONE BIO INNOVATIONS, INC.
September 5, 2019	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / Ospraie Ag Science Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York, NY 10022 (212) 602-5000 (Name, Add
August 19, 2019	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13D (including amendments thereto) with respect to the Common Stock of Marrone Bio Innovations, Inc.
August 19, 2019	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / ARDSLEY ADVISORY PARTNERS - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No.
August 12, 2019	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / Ospraie Ag Science Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 57165B106 (CUSIP Number) Ospraie Ag Science LLC c/o Dwight Anderson 437 Madison Avenue, 28th Floor New York NY 10022 (212) 602-5000 (Name, Addr
August 9, 2019	EX-10.2	Amended lease agreement April 25, 2019 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (the “First Amendment”) is made and entered into as Of April 25, 2019 by and between SAN CARLOS RETAIL VENTURE, L.
August 9, 2019	10-Q/A	MBII / Marrone Bio Innovations, Inc. 10-Q/A - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 Or [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number
August 8, 2019	EX-99.1	Marrone Bio Innovations, Inc. Reports Second-Quarter and First-Half 2019 Financial Results Second Quarter 2019 Revenues Rose 22 Percent to $7.0 Million; First Half 2019 Revenues Increased 56 Percent to $15.7 Million Company Also Announces Pro Farm Ac Marrone Bio Innovations, Inc. Reports Second-Quarter and First-Half 2019 Financial Results Second Quarter 2019 Revenues Rose 22 Percent to $7.0 Million; First Half 2019 Revenues Increased 56 Percent to $15.7 Million Company Also Announces Pro Farm Acquisition to Accelerate Growth, and Establishes Financing Facility to Fund Acquisition and Operations DAVIS, Calif. – August 8, 2019 – Marrone Bio Inn
August 8, 2019	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2019 MARRONE BIO INNOVATIONS, INC.
August 8, 2019	EX-10.3	Registration Rights Agreement, dated August 6, 2019, by and between Marrone Bio Innovations, Inc. and the investors named therein. REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 6, 2019, by and among Marrone Bio Innovations, Inc.
August 8, 2019	EX-99.2	Marrone Bio announces financing facility to fund future operations and strategic acquisitions Marrone Bio announces financing facility to fund future operations and strategic acquisitions DAVIS, Calif.
August 8, 2019	EX-4.2	Form of Warrant issued by Marrone Bio Innovations, Inc. in connection with the August 6, 2019 Warrant Agreement NEITHER THE ISSUANCE AND SALE OF THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
August 8, 2019	EX-4.1	Warrant Amendment and Plan of Reorganization Agreement, dated August 6, 2019, by and among Marrone Bio Innovations, Inc., Ospraie AG Science LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval. WARRANT AMENDMENT AND PLAN OF REORGANIZATION AGREEMENT This Warrant Amendment and Plan of Reorganization Agreement (this “Agreement”) is entered into at 3:00 P.
August 8, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2019 MARRONE BIO INNOVATIONS, INC.
August 8, 2019	EX-10.1	Share Purchase Agreement, dated August 7, 2019, by and among Marrone Bio Innovations, Inc., Pro Farm Technologies OY, the Shareholders and Matti Tiainen as Shareholders’ Representative. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
August 8, 2019	EX-99.1	Marrone Bio announces transformative acquisition of Pro Farm Technologies in the $4.6 billion seed- and soil-treatment market Pro Farm products expected to substantially accelerate growth trajectory Marrone Bio announces transformative acquisition of Pro Farm Technologies in the $4.
August 8, 2019	EX-10.2	First Amendment to Lease, dated April 25, 2019, by and between San Carlos Retail Venture, L.P., Verbenta URP Partners, LP, Fulcrum URP Investors, LP, Gray & Affrime Family LLC, and Flores-Lopez Anvary LLC. FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (the “First Amendment”) is made and entered into as Of April 25, 2019 by and between SAN CARLOS RETAIL VENTURE, L.
August 8, 2019	10-Q	MBII / Marrone Bio Innovations, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 Or [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 Marron
June 7, 2019	S-8	MBII / Marrone Bio Innovations, Inc. S-8 - - As filed with the Securities and Exchange Commission on June 7, 2019 Registration No.
June 3, 2019	8-K	Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2019 MARRONE BIO INNOVATIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36030 20-5137161 (State or other jurisdiction (Commission (I.R.S. Employ
May 10, 2019	10-Q	MBII / Marrone Bio Innovations, Inc. 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 Or [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-36030 Marro
May 9, 2019	EX-99.1	Marrone Bio Innovations, Inc. Reports First-Quarter 2019 Financial Results First-Quarter 2019 Revenues More Than Doubled to $8.7 Million, with Gross Margins of 57 Percent DRAFT: May 9, 2019 First Quarter 2019 Results Marrone Bio Innovations, Inc. Reports First-Quarter 2019 Financial Results First-Quarter 2019 Revenues More Than Doubled to $8.7 Million, with Gross Margins of 57 Percent DAVIS, Calif. – May 9, 2019 – Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable biopesticide and plant health solutions, has provided its financial
May 9, 2019	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2019 MARRONE BIO INNOVATIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36030 20-5137161 (State or other jurisdiction (Commission (I.R.S. Employe
April 30, 2019	DEF 14A	Marrone Bio Innovations, Inc. 2019 Employee Stock Purchase Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo
April 26, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 22, 2019 MARRONE BIO INNOVATIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36030 20-5137161 (State or other jurisdiction (Commission (I.R.S. Empl
April 26, 2019	EX-3.1	Fifth Amended and Restated Bylaws of Marrone Bio Innovations, Inc. Exhibit 3.1 FIFTH AMENDED AND RESTATED BYLAWS OF MARRONE BIO INNOVATIONS, INC., a Delaware Corporation TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE 2 STOCKHOLDERS’ MEETINGS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 1 Section 2.3 Special Meetings 1 Section 2.4 Notice of Meetings 2 Section 2.5 Quorum and Voting 3 S
April 5, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2019 MARRONE BIO INNOVATIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36030 20-5137161 (State or other jurisdiction (Commission (I.R.S. Emplo
March 29, 2019	10-K	MBII / Marrone Bio Innovations, Inc. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36030 Marron
March 18, 2019	EX-99	MARRONE BIO INNOVATIONS, INC. CORPORATE GOVERNANCE GUIDELINES MARRONE BIO INNOVATIONS, INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors (the “Board”) of Marrone Bio Innovations, Inc. (the “Company”), acting on the recommendation of its Nominating and Corporate Governance Committee, has developed and adopted a set of corporate governance principles to provide the framework for the governance of the Company and to assist the Board in the exercise of
March 18, 2019	EX-3.1	Amended and Restated Bylaws of the Company Exhibit 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF MARRONE BIO INNOVATIONS, INC., a Delaware Corporation TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE 2 STOCKHOLDERS’ MEETINGS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 1 Section 2.3 Special Meetings 1 Section 2.4 Notice of Meetings 2 Section 2.5 Quorum and Voting 3
March 18, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2019 MARRONE BIO INNOVATIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36030 20-5137161 (State or other jurisdiction (Commission (I.R.S. Empl
March 18, 2019	NT 10-K	MBII / Marrone Bio Innovations, Inc. SEC FILE NUMBER 001-36030 CUSIP NUMBER 57165B106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 14, 2019	EX-99.1	Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2018 Financial Results Fourth Quarter 2018 Revenues Grew 72% to $5.7 Million; Fiscal Year 2018 Revenues Increased 17% to $21.2 Million Fourth Quarter 2018 Gross Margins Expanded to 50 Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2018 Financial Results Fourth Quarter 2018 Revenues Grew 72% to $5.7 Million; Fiscal Year 2018 Revenues Increased 17% to $21.2 Million Fourth Quarter 2018 Gross Margins Expanded to 50.5%; Annual Gross Margins Expanded to 48.6% DAVIS, Calif. – March 14, 2019 – Marrone Bio Innovations Inc. (NASDAQ: MBII) (MBI), an international leade
March 14, 2019	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2019 MARRONE BIO INNOVATIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36030 20-5137161 (State or other jurisdiction (Commission (I.R.S. Empl
February 26, 2019	S-8	MBII / Marrone Bio Innovations, Inc. S-8 As filed with the Securities and Exchange Commission on February 25, 2019 Registration No.
February 25, 2019	SC 13G/A	MBII / Marrone Bio Innovations, Inc. / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 57165B106 (CUSIP Number) February 21, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 25, 2019	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene
February 14, 2019	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene
February 14, 2019	SC 13G/A	MBII / Marrone Bio Innovations, Inc. / WADDELL & REED FINANCIAL INC - MARRONE BIO INNOVATIONS, INC. Passive Investment Marrone Bio Innovations, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 1* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 57165B106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
February 14, 2019	EX-99.3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
February 14, 2019	SC 13G/A	MBII / Marrone Bio Innovations, Inc. / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 57165B106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 14, 2019	EX-99.1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
February 14, 2019	EX-99.2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
February 12, 2019	SC 13D/A	MBII / Marrone Bio Innovations, Inc. / ARDSLEY ADVISORY PARTNERS - SC 13D/A Activist Investment SC 13D/A 1 marrone13da1.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No. 1) (Rule 13d-101) information to be included in statements filed pursuant to rules 13d-1(a) and amendments thereto filed pursuant to rule 13d-2(a)1 Marrone Bio Innovations, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 57165B106 (CUSIP Number) Steve Napoli

MBII / Marrone Bio Innovations Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)